Real World Evidence 2013

Provide robust evidence on the real-world value of treatments to transform healthcare

Promote relative effectiveness, build strategic partnerships, and bring therapies to market – Case Studies from Tehseen Salimi - VP of Global Value & Evidence Development at Sanofi, David Memel - VP of HEOR at Boehringer Ingelheim, Marc Berger - VP of Real World Data & Analytics at Pfizer & Brian Bradbury – Director, Center for Observational Research at Amgen

Tehseen Salimi VP Global Evidence and Value Development Sanofi	David Memel VP – HEOR Boehringer Ingelheim	Marc Berger VP Real World Data & Analytics Pfizer	Matt Portch Vice President of Commercial Model Innovation Pfizer, Primary Care Business Unit

Click here to download your free copy of the eyeforpharma Real World Evidence 2013 brochure

Know how US healthcare IT changes impact your data collection methods.  NIH OBSSR Director Robert Kaplan delivers a Case Study will show the new generation of analysis methods to deal with massive EMR datasets - Harmonize your data-capture strategy.

Policy changes can critically effect your evidence generation investments. Meet D.C. insiders - an advisor to the Senate Health Committee speaks on the release of Medicare and Medicaid claims data, commercialization and path to market success. Also hear an exclusive case study industry perspective from Johnson & Johnson Senior Director – Health Policy, Robert Donnelly.

Dr. Robert Kaplan Director - Office of Behavioral and Social Sciences Research (OBSSR) National Institutes of Health	Stephanie Carlton Health Policy Advisor United States Senate - Health Committee	James Sorace Senior Medical Officer HHS - ASPE	Robert Donnelly Senior Director, Health Policy Johnson & Johnson

Click here to download your free copy of the eyeforpharma Real World Evidence 2013 brochure

Discover treasure troves of Provider/ACO data-sets to understand why they are interested in collaborating with pharma on the evidence generated about the real-world effects of medical treatments – from Brian Wells, AVP at Penn Medicine, John Lynch, Executive Director at CT Center for Primary Care & Mohit Kaushal, Partner at Aberdare Ventures (ex-CSO at West Health)

Brian Wells AVP Health Technology and Academic Computing University of Pennsylvania Health Syste	John Lynch Executive Director CT Center for Primary Care	Mohit Kaushal, MD Partner Aberdare (Formerly Chief Strategy Officer & EVP at West Health)	Craig Richardson Head of Access to External Data Janssen Pharmaceuticals (a Johnson & Johnson company)

Understand the real-world data opportunities and challenges in emerging markets in Asia and globally from Joe DiCesare, VP Global HEOR at Novartis & Jason Liu, Global Head HEOR at Pfizer.

Network with solution providers that have the insights, tools, technologies and industry knowledge to transform your data into actionable evidence.

Jill Sackman Senior Consultant Numerof & Associates	William H. Crown, Ph.D. Chief Scientific Officer Optum (President of ISPOR)	Joe DiCesare Vice President, Global Health Economics & Outcomes Research Novartis	Steve LoSardo Director, Health Industries Advisory, Business Intelligence and Analytics PricewaterhouseCoopers

Click here to download your free copy of the eyeforpharma Real World Evidence 2013 brochure

Don’t just take our word for it…

The expertise of the various speakers and the relevance of the discussion topics made the conference worthwhile and an opportunity for learning.

Brian Bradbury, Director - Center for Observational Research, Amgen

What set this particular meeting apart from others I have attended was the quality of the panel discussions, both in terms of the experience and expertise of the speakers as well as content.

Clark Paramore, Senior Research Scientist - Health Economics, UBC

“A good networking & learning opportunity on topics essential for healthcare improvement. This meeting has global experts willing to share the spirit of open innovation. The panel discussions offer valuable insights with relevant and pragmatic content.”

Tehseen Salimi, VP Global Evidence and Value Development, Sanofi

From what I can see, the 2013 program stands head and shoulders above the more recent entrants to this area. It’s the variety of content, delivery and senior level attendance that I’m most excited about.

Mike Rea, Partner, IDEA Pharma

Why Real World Evidence 2013 is a must attend...

• Case Studies You Need to Hear:  From Sanofi, Amgen, Pfizer, Northeastern, Tufts, NIH, Penn Health, and Johnson & Johnson
• Understand the risks of not adapting to disruptions that real world data have created for your business
• Look into the future and learn why building a strategy for data access, collection, and integration will be the basis for your value story
• Make a Case for Market Access:  Take action, partner with payers, providers, and vendors to link your value chain and transform raw data into evidence
• Build a strategy for expanding RWE operations in emerging markets like China
• Know the laws on data access and privacy by learning from legal experts
• Use Statistics for Success:  and think about how CER, observational studies, retrospective studies, and prospective studies are best conducted